Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 852

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Li speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting to discuss early results from a trial of anti-HER2 ado-trastuzumab emtansine in HER-2 amplified tumours detected in sites beyond breast and gastric diseases.

He outlines the trial design and recruitment scheme, in which evidence of response in a small patient cohort led to further recruitment in that indication.

Among these early results, Dr Li contrasts the total lack of response in HER-2 amplified colorectal tumours to the 100% response rate in salivary tumours, and discusses further trial expansion to further validate these findings.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation